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Opinion statement
More attention has been paid to the mitral valve (MV) than the tricuspid valve (TV), and
this relative paucity of data has led to confusion regarding the timing of TV surgery. We
review the American College of Cardiology/American Heart Association and European
Society of Cardiology guidelines to identify areas of concordance (severe tricuspid re-
gurgitation [TR] in a patient undergoing mitral valve surgery); discordance (less than
severe TR but with markers for late TR recurrence such as pulmonary hypertension, a
dilated TV annulus, atrial fibrillation, permanent transtricuspid pacing wires and
others); and disagreement (surgery for primary TR). We provide our perspective from
Northwestern University on these issues and where the guidelines are silent (TR in
patients undergoing non-mitral valve operations). Finally, we review recent publica-
tions on the results of TV repair and replacement. Although there have been scant pub-
lications in the past, there have been more useful publications in recent years to guide
our decision making.
Introduction
The tricuspid valve (TV) has not received as much at-
tention as the aortic valve (AV) or mitral valve (MV),
and hence has been referred to as the “forgotten
valve.” Significant tricuspid regurgitation (TR) may
be clinically silent for a prolonged period, during
which time progressive right ventricle (RV) dilatation
and dysfunction may develop, similar to changes that
can occur with asymptomatic mitral regurgitation
(MR) and its’ effect on LV function. Eventually the
TR patient may be managed with diuretics for symp-
toms and only considered for surgery after advanced
RV dysfunction, and even liver dysfunction or cirrho-
sis, have developed. It should be no surprise, there-
fore, that results from the Society of Thoracic
Surgeons (STS) Database indicate that TV surgery is
the most high-risk valve operation in terms of morbid-
ity and mortality [1]. Although MV surgery has
evolved over the past few decades toward progressive-
ly earlier intervention, even in selected asymptomatic
patients, no such evolution has occurred in TV surgery
yet [2, 3￿￿]. The relative paucity of articles on the TV
compared with AV and MV, and no randomized trials,
contribute to this problem. In this article, we review
and compare the US and European Guidelines regard-
ing TV surgery, data supporting these guidelines, re-
cent outcome data for TV surgery and repair results,
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MV surgery.
US and European guidelines on the management
of valvular heart disease
Both the American College of Cardiology/American
Heart Association (ACC/AHA) and the European Soci-
ety of Cardiology (ESC) have produced extensive
documents on the management of heart valve disease,
including separate sections on TV surgery [2, 3￿￿].
There are some areas of concurrence and others of dis-
agreement (Table 1). Both list a class I indication to
perform TV repair for severe TR in patients who are un-
dergoing MV surgery, and that reflects the standard of
practice for most surgeons. Both guidelines are silent
about performing TV surgery when a surgeon is there
for coronary bypass, aortic valve replacement (AVR),
or other cardiac surgery. At Northwestern, we would
typically perform TV repair in these situations. The
ESC Guidelines also list TV surgery as a Class I indica-
tion in the case of severe primary TR (or tricuspid ste-
nosis) with symptoms despite medical therapy,
without severe RV dysfunction. Somewhat surprising-
ly, the US guidelines only list this as “reasonable”
and a class IIa indication. Perhaps this reflects the re-
luctance to operate on some of these patients who
have already developed irreversible RV dysfunction
as the natural history of TR has progressed, but it is
one of the rare times that valve disease with symptoms
is not listed as a Class I indication for surgery in the
guidelines.
Class II indications show considerable differences
between the two documents. The ESC lists a IIa recom-
mendation for severe TR and symptoms in the unfor-
tunately too-common scenario seen after left-sided
valve surgery (without left-sided valve dysfunction,
RV dysfunction, or pulmonary hypertension). The US
guidelines are silent in this circumstance. Although
the repair rate for TV is increasing in the United States
(compound annual growth rate of 16.4%) per STS da-
ta (Table 2)[ 1, 4], untreated TR may cause symptoms
after MV surgery such that the above clinical situation
is not uncommon. However, as the patient will now
be a reoperation, clinicians are reticent to perform a
reoperative surgery. The best strategy would be to
avoid this situation by the more liberal use of TV
annuloplasty (TVA) at the initial surgery, and this is
reflected in the ESC guidelines; the US guidelines are
more conservative, however. It is not clear if the US
guidelines were meant to reflect general US practice,
or whether they influence t h ep r a c t i c ea n dt h e r e f o r e
TV surgery is less common here. The ESC gives a Class
IIa indication for moderate secondary TR with a dilated
annulus (940 mm) in a patient undergoing left-sided
valve surgery [2]. The US guidelines say TVA “may
be considered” (Class IIb) when there is TV annular di-
latation or pulmonary hypertension [3￿￿].
Perhaps one of the most important differences,
however is that the US guidelines give a class III in-
dication (not indicated) in asymptomatic patients
with TR whose pulmonary artery systolic pressure
(PASP) is less than 60 mmHg in the presence of a
normal MV [3￿￿]. This is interesting because they
now have elevated MV repair to a Class IIa indica-
tion in asymptomatic patients if there is a 90%
chance of success in an experienced center. With
the exception of some organic TR cases, the vast ma-
jority of TV surgeries are repair, even in the less ex-
perienced US centers. The ESC guidelines for mild or
no symptoms with severe isolated TR, and progres-
sive dilatation or deterioration of RV function, give
this a IIb (may be considered) recommendation
[2]. This is more reflective of the insidious natural
history of TR on RV function. It also mirrors the phi-
losophy behind earlier intervention in patients with
asymptomatic severe MR to avoid the deleterious
effects of inevitable progressive LV dysfunction. Both
guidelines reflect a limited ability to analyze the
course of functional TR due to the paucity of long-
term data, difficulty quantifying the amount of TR,
and because they are derived mostly from a consen-
sus of experts, retrospective studies, or registries.
TV and other valve surgery Data from the STS demon-
strates theTRrepairrateforpatientsundergoingisolated
MV repair with preoperative 4+ TR was 80%; for those
with 3+ TR it was 30%; and for those with 2+ TR it was
5%. Data from our Northwestern database show those
rates for 4+ are 100% (93% repair, 7% replace), 50%
for3+TR,and21%for2+TR.Forthe50%ofNorthwest-
ernpatientswithuncorrected3+TR,theseweregenerally
elderly patients with previous surgeries, no history of
right heart failure, and resolution of TR before surgery.
Some patients with ≤2+ TR underwent repair, if there
was a history of right heart failure, left ventricular ejec-
tion fraction (LVEF) G35%, pulmonary hypertension,
and/or TV annular diameter 940 mm as measured in
any dimension by intra-operative transesophageal echo-
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ESC guidelines. We used a rigid remodeling ring, size
26 mm or 28 mm, in 93% of patients. If the TV was se-
verely tethered or had extensive leaflet damage, it was
replaced (chord-sparing) in 7% of patients with a bio-
prosthetic valve. Permanent pacemakers (PPM) or im-
plantable cardioverter-defibrillators (ICD) were
removedandreplacedwithepicardialpacingwiresorse-
Table 1. Comparison of guidelines for tricuspid valve surgery
ACC/AHA guidelines [3]
a ESC guidelines [2]
b
Class I Class IC
1. TV repair is beneficial for severe TR in patients with MV
disease requiring MV surgery (Level of Evidence: B)
Severe TR in a patient undergoing left-sided valve surgery
Severe primary TR and symptoms despite medical therapy
without severe right ventricular dysfunction
c
Severe TS (± TR), with symptoms despite medical therapy
(Percutaneous technique can be attempted as a first
approach if TS is isolated)
Severe TS (± TR) in a patient undergoing left-sided valve in-
tervention (Percutaneous technique can be attempted as a
first approach if TS is isolated)
Class IIa Class IIaC
1. TV replacement or annuloplasty is reasonable for severe
primary TR when symptomatic. (Level of Evidence: C)
c
Moderate organic TR in a patient undergoing left-sided valve
surgery
2. TV replacement is reasonable for severe TR secondary to
diseased/abnormal tricuspid valve leaflets not amenable
to annuloplasty or repair. (Level of Evidence: C)
Moderate secondary TR with dilated annulus (940 mm) in a
patient undergoing left-sided valve surgery
d
Severe TR and symptoms, after left-sided valve surgery, in the
absence of left-sided myocardial, valve, or right ventricular
dysfunction and without severe pulmonary hypertension
(systolic pulmonary artery pressure 960 mmHg)
Class IIb Class IIbC
1. Tricuspid annuloplasty may be considered for less than
severe TR in patients undergoing MV surgery when there
is pulmonary hypertension or tricuspid annular dilata-
tion. (Level of Evidence: C)
d
Severe isolated TR with mild or no symptoms and progressive
dilatation or deterioration of right ventricular function
e
Class III
1. TV replacement or annuloplasty is not indicated in
asymptomatic patients with TR whose pulmonary artery
systolic pressure is G 60 mmHg in the presence of normal
MV. (Level of Evidence: C)
e
2. TV replacement or annuloplasty is not indicated in
patients with mild primary TR. (Level of Evidence: C)
ACC/AHA American College of Cardiology/American Heart Association; ESC European Society of Cardiology; MV mitral valve; TR tricuspid
regurgitation; TS tricuspid stenosis; TV tricuspid valve
aFrom Bonow RO, Carabello BA, Chatterjee K, et al.: 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the man-
agement of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease):
endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of
Thoracic Surgeons. Circulation 2008, 118(15):e523–661, with permission of the publisher. (Copyright © 2008, the American Heart
Association)
bFrom Vahanian A, Baumgartner H, Bax J, et al.: Guidelines on the management of valvular heart disease: The Task Force on the Manage-
ment of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal 2007, 28(2):230–268, with permission of
the publisher. (Copyright © 2007, the European Society of Cardiology)
cDifference in approach to patients with symptomatic primary TR
dDifference in approach to patients with less than severe TR
eDifference in approach to patients with asymptomatic primary TR
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are known to reduce repair durability [5].
Class II indications for surgery
Annular Size Dreyfuss et al. [6] used tricuspid annular
dilatation as the indication for TV repair, regardless of TR
grade.Datafromtheir long-term prospective seriesof 311
patients with no clinically significant preoperative TR in
98% (preoperative ≤1+ TR in 88%) showed that 148
patients had a large annulus diameter (≥70 mm) and
were treated by TVA. Preoperative mean TR grade was
0.7 in untreated (n=163) and 0.9 in TVA groups (n=
148). Mean follow-up was 4.8 years. TR increased by ≥2
grades in the uncorrected TR group and was more than
intheTVAgroup(48%vs2%;PG0.001).Theuncorrected
group demonstrated significant worsening in New York
Heart Association (NYHA) class (1.6 vs 1; PG0.0001)
and similar survival (85% vs 90%; P = NS) at 10 years.
A similar study by Sarraj et al. [7] used the cut-off value
of tricuspid diameter 921 mm/m
2 (measured by four-
chamber echocardiogram) to perform tricuspid repair in
17 patients with severe TR, and PASP G60 mmHg in
53%.At2.5yearsoffollow-up,theauthorsobservedasig-
nificant decrease of mean TR from 3.5 to 1.6 (PG0.001)
and substantial reduction of moderate/severe dilatation
of TV annulus from 100% to 0 (PG0.001). No operative
mortality was reported and overall mortality was 6%.
Pulmonary artery hypertension and ischemic
cardiomyopathy In a study of 237 patients with preop-
erative symptomatic severe TR (960%), NYHA III/IV
(950%), and mildly reduced EF, Ghanta et al. [8]o b -
served that after tricuspid repair, patients with recurrent
TR had a higher postoperative PASP compared with
patients without recurrent TR (52 mmHg vs 43 mmHg).
InastudyofpatientswithlowEFandpulmonaryhyper-
tension, significant ≥3+ TR was higher compared with
patients with no pulmonary hypertension (37% vs 3%;
PG0.0001) during 2 years of follow-up after TV and
MV repair [9￿] .A b s e n c eo fr e s i d u a lT Ra f t e rT Vr e p a i r
in 17 patients with preoperative symptomatic severe
TR was associated with significant reduction of moder-
ate/severe pulmonary hypertension from 94% to 30%
(PG0.002)[7].Inastudyofpatientswithpredominantly
nonischemic mitral disease undergoing concomitant TV
repair, significant decrease of residual TR from 42% to
3% (PG0.001) was associated with a substantial reduc-
tion of PASP from 48 mmHg to 34 mmHg (PG0.001)
[10]. These studies suggest thatelevated PASPnegatively
impacts mid-term recurrent TR.
Matsunaga and Duran [11] reported in 70 patients
with ischemic mitral regurgitation (IMR), after revas-
cularization and MV surgery, that the incidence of TR
increased from 25% at G1 year to 74% at ≥3 years, in-
dependent of whether TR was corrected or ignored. Re-
sidual significant TR was 64% and associated with the
return of functional MR in 31% at last follow-up. Sim-
ilarly, Bove et al. [12] reported in 78 IMR patients a
prevalence of significant TR in 22% and recurrent
MR was present in 9% during 2 years of follow-up af-
ter mitral repair. These studies suggest the relationship
of functional TR with functional MR, and mutually re-
lated with poor LV function. Calafiore et al. [13￿] have
demonstrated that functional TR progression is not re-
lated to recurrent MR in patients with low EF but
impacts prognosis when left untreated. MV and TV sur-
gery was performed in 110 patients with severe IMR
(EF ≤35%) and co-existent significant TR. Lower resid-
ual TR was observed in the TV repair group compared
with the uncorrected group (5% vs 40%; PG0.001).
Both groups had similar recurrent MR at 5%. Five-year
survival rate was 75% in TV repair group versus 45%
in the no-repair group (P=0.004).
Table 2. Number of mitral valve and tricuspid valve
procedures
a
Year MV repairs ± CAB, n TV surgeries, n
2000 4,853 1,786
2001 5,926 2,276
2002 7,776 3,256
2003 8,404 4,086
2004 8,287 4,466
2005 9,189 5,271
2006 9,930 5,965
2007 10,276 6,088
2008 11,203 6,684
2009 11,347 7,001
CAB coronary artery bypass; MV mitral valve; TV tricuspid valve
aA recent report by the Society of Thoracic Surgeons Database
showed a growing number of MV and TV surgeries from 2000-
2009. TV surgery procedures increased at a compound annual
growth rate of 16.4%
Data from The Society of Thoracic Surgeons Adult Cardiac Surgery
Database Spring 2010 Report [4]; with permission
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The ACC/AHA practice guidelines appear to be incon-
sistent in interpreting studies concerning asymptomat-
ic or mild primary TR with apparently preserved RV
hemodynamics and no annular dilatation. TV surgery
is not indicated in asymptomatic and mild primary
TR patients with PASP G60 mmHg in the absence of
MV disease according to the established guidelines
(Table 1)[ 3￿￿]. As explained in the guidelines, moder-
ate or severe TR may be present without classic clinical
features. Likewise, they state “Patients with severe TR
of any cause have a poor long-term outcome because
of RV dysfunction and/or systemic venous congestion”
[3￿￿]. A study from the Mayo Clinic examined 26
asymptomatic TR patients (NYHA functional class I
a n dn oh i s t o r yo fh e a r tf a i l u r e )c a u s e db yt r i c u s p i d
flail leaflets [14]. By 10 years, cumulative high event
rates were observed in 75% of patients with symptoms
of heart failure, atrial fibrillation (AF), surgical inter-
vention, or death (Fig. 1). TV repair was performed
in 82% of patients with a low mortality (3%) and
marked symptomatic improvement in 88% of
patients. Conversely, excess mortality and high mor-
bidity were observed in the unoperated group. The
authors suggest that surgical intervention should be
considered early in the course of the disease before
the occurrence of irreversible consequences. ACC/
AHA guidelines suggest this is not indicated (Class
III) but note that if left untreated, it will lead to a
“poor long-term outcome.” At Northwestern, we be-
lieve early surgery is justified, as this is an insidious
disease with a definite mortality and morbidity risk.
Asymptomatic patients may have clinically silent se-
vere RV enlargement with apparently normal RV pres-
sure, and no pulmonary hypertension and mitral
disease. Messika-Zeitoun et al. [14] initially found on-
ly 27% with severe right-sided chamber enlargement
and the rest had normal right-sided chamber dimen-
sion. However, by 5 years, patients had developed se-
vere right-sided chamber enlargement, even in those
who did not have any chamber enlargement at initial
presentation (39% no enlargement vs 87% with en-
largement; PG0.01). This prolonged latent period led
to a high 15-year event rate (69% with symptoms
of heart failure, AF, cardiac surgery, or death). This is
particularly important because patients with post-
traumatic lesions are usually young when complica-
tions occur. The outcome was characterized by excess
mortality (36% at 10 years or 3.8% yearly) [14]. Being
“asymptomatic” does not guarantee that the heart has
not undergone TR-related ventricular changes. There-
fore, like asymptomatic MR with flail leaflets, early
surgery should be favored, particularly because suc-
cessful repair is highly likely.
Factors in the development of recurrent TR
Atrial fibrillation Datafromalong-termstudyin90MV
surgerypatientswithpreoperativeAFandnoTRdemon-
strated that severeTRdevelopedin7.5%and wasassoci-
ated with an event-free survival rate of 71% at 13 years
[15].Inanotherstudyfromthatgroup,significantreduc-
tionof recurrentTR was achieved in 38% of MV patients
undergoing concomitant Maze procedure compared
with no-Maze patients (15% vs 40%; P=0.005) with
an average follow-up of 7.6 years [16]. Similarly, a
case-matched study by Stulak et al. [17￿] from the Mayo
Clinic found that in mitral repair patients undergoing
concomitant Maze, a much lower recurrent TR rate was
observed compared with the untreated AF group (9%
vs 45%; PG0.001) at last follow-up. Left atrial size con-
tinued to increased significantly in patients with persis-
tent AF during follow-up when compared with Maze
patients who converted to normal sinus rhythm (P=
0.05) [17￿]. Another study by Stulak et al. [18￿] found
that patients with preoperative moderate TR and no his-
tory of AF may develop late-onset AF (5 years, 11%;
10years,23%)withareducedsurvivalof62%,evenafter
successful correction of MR and TR.
PermanentpacemakerorICDleads Linetal.[19]reviewed
their series of TV surgery due to symptomatic severe TR
caused by previously placed PPM or implanted ICD
leads in 41 patients. Mean time from PPM or ICD place-
menttoreoperationwas6years.ThecauseofTRwasim-
pingement of the lead on the TV leaflets in 40%, leaflet
perforation, entanglement of the TV apparatus, and
adhesionoftheleadtotheTVleaflet.Halfofthepatients
underwent TV repair in the absence of extensive TV leaf-
let damage. Otherwise, the lead was removed or reposi-
tioned away from the affected leaflet, secured in the
recessofeithertheposteroseptaloranteroposteriorcom-
missure, or the defect in the leaflet was suture-repaired.
The rest of the patients underwent TV replacement
because of extensive leaflet damage, and the pacing lead
waspositionedexternaltothesewingringoftheprosthe-
sis. Symptomatic improvement was observed during
an 8-year follow-up. McCarthy et al. [5] showed that
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PPM had 3+ or 4+ TR, almost double the incidence of
those without a pacemaker (P=0.04). Similarly, Navia
et al. [20￿] from a later Cleveland Clinic series found
in the 15% of patients with preoperative PPM, signifi-
cantTR was present in45% 5 years after TVrepair. These
studiessuggestremovingPPMandreplacingwithepicar-
dial leads atthe timeofsurgery may bethe best solution
[5].
TV tethering, ventricular dilatation and dysfunction Fukuda
et al. [21] showed that measuring distance and area
of TV tethering is a reliable diagnostic criterion to
predict the severity of early residual TR after TV
r e p a i r .L a t e r ,F u k u d ae ta l .[ 22]r e p o r t e di np a t i e n t s
with preoperative tethering height greater than
1.0 cm, repair failure was 55% immediately after
repair, suggesting that tethering height is also a
predictive factor for greater residual TR. A recent
study used TV leaflet tethering distance of 98m m
or a tethering area of 916 mm
2 as the threshold
for performing an adjunctive procedure (pericardial
patch to anterior leaflet) to lessen leaflet tethering
[23￿]. Low recurrent TR of 2% and 8% of patients
was realized at 1 month and 1 year, respectively.
Figure 1. Outcomes of Mayo
Clinic patients with primary
tricuspid regurgitation (TR)
caused by flail tricuspid valve
(TV) leaflets. A Observed survival
compared with expected survival
for a matched population in the
United States. Left panel shows
excess mortality observed in
patients with tricuspid flail
leaflets with or without associat-
ed disease. Right panel shows
high mortality of patients with
symptomatic and asymptomatic
primary TR with exclusion of
cohort analyzed from left panel
of TR patients with associated
disease. B Incidences of com-
bined endpoint of symptoms,
heart failure, new atrial fibrilla-
tion, cardiac surgery, or death in
asymptomatic TR patients.
(Reprinted from Messika-Zeitoun
D, Thomson H, Bellamy M, et al.
Medical and surgical outcome
of tricuspid regurgitation caused
by flail leaflets. Journal of Tho-
racic and Cardiovascular Surgery
2004, 128(2):296–302, with per-
mission from Elsevier. Copyright
© 2003, the American Association
for Thoracic Surgery.).
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icant correlation of higher RV pressures and TR
severity in 39 patients after TV repair. Patients
with early postoperative LV dysfunction had sus-
tained higher RV pressures after follow-up compared
with patients with preserved LV function. de Bonis
et al. [9￿] reported outcomes after mitral repair
in 78 patients with dilated cardiomyopathy (EF
≤31%) and co-existent TR ≤2+ and RV dysfunction.
U n c o r r e c t e dT Rp r o g r e s s e dt oT Rs e v e r i t y≥2i n
18%.
Summary
Insummary,thereisasignificantriskforresidualTRifitis
left untreated in patients with a dilated annulus, ischemic
cardiomyopathy,andpulmonaryhypertension.Theseare
patients that we approach more aggressively at North-
western, similar to ESC guidelines. There is a significant
riskforrecurrentTRafterTVAforpatientswithpermanent
pacing wires, a history of AF, and RV dysfunction with di-
latation and leaflet tethering. All these factors need to be
properly weighed in regards to the decision whether or
not to perform TV surgery and how to perform TVA.
Treatment
Operative Techniques and Outcomes
Repair Techniques: Ring and Suture
& The goal of tricuspid repair is to reduce annular dilatation and lessen
TV leaflet tethering, thereby stabilizing the annulus and increasing
leaflet coaptation.
& Techniques broadly include 1) rings, such as flexible rings and bands,
and rigid remodeling rings [5, 10, 20￿, 22, 24, 25]; 2) Suture annu-
loplasties, such as bicuspidization [8], partial purse-string (De Vega),
modified De Vega; and 3) pericardial annuloplasty [5, 20￿]. Other
techniques may include 1) edge-to-edge “Clover” technique by su-
turing the free margins of the tricuspid leaflets in conjunction with
ring annuloplasty [26]; 2) anterior tricuspid leaflet augmentation to
increase leaflet coaptation and relief of tethered leaflets [27￿]; and 3)
a very preliminary RV reduction technique used to plicate the RV wall
by placement of two strips of felts on the epicardial surface. This
method reduced the RV cavity and approximated the papillary
muscles [28].
& Matsuyama et al. [29] reported by 3 years, 3+4+ TR redeveloped in
6% of patients in the ring group compared with 45% in the DeVega
group. Navia et al. [20￿] reported by 3 months that 3+4+ TR was
present in 11% of patients. By 5 years, significant TR redeveloped in
10% to 16% in the ring group; however, a trend for higher incidence
of TR was observed in the suture group (19% for Kay and 24% for De
Vega). Ghanta et al. [8] found TR recurrence was 31% in the ring
group compared with 25% in the “bicuspidization” group at average
follow-up of 3 years. In another study, a newly developed suture
pericardial strip annuloplasty was compared with conventional su-
ture annuloplasties [30]. By 3 years, 3+4+ TR redeveloped in 10% in
the pericardial strip group versus 16% in the conventional group.
Long-term studies by Tang et al. [31] demonstrated significantly
better freedom from recurrent TR in the ring than suture repairs (83%
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function, ring repairs proved to be more durable than suture repairs.
Ring annuloplasty predicted better long-term and event-free survival.
Mid-term studies of ring, suture, and pericardial annuloplasties have
an 8% to 14% prevalence of rapid 3+4+ TR recurrence within a week
of surgery [5, 8, 20￿, 22, 30]. Risk factors for repair failure included
higher preoperative TR [5, 8, 20￿, 30], higher PASP [8], larger ring
size, MV replacement rather than repair, worse LV dysfunction [5],
increased LV remodeling [20￿], suture [30] and Peri-Guard annulo-
plasties), and presence of pacemakers [5].
Anterior tricuspid leaflet augmentation: early studies
& Dreyfuss et al. [27￿] reported 15 patients with dilated cardiomyop-
athy and post-heart transplantation undergoing isolated tricuspid
repair due to severe TR, annular dilatation (≥40 mm), and tethering
(height ≥than 8 mm). Leaflet augmentation concomitant with ring
annuloplasty was performed. Mean follow-up was 6 to 20 months.
Results of pre-discharge and last follow-up echocardiography
reported no residual or recurrent TR. Coaptation length of at least
5 mm was successful in all patients. The tethering height was un-
changed with better leaflet coaptation. Available data in 5 patients
were reported to be in class I or II. Roshanali et al. [23￿] reported 210
patients undergoing concomitant MV surgeries. Half of the patients
received ring and suture De Vega annuloplasties. High preoperative
tethering index (distance 98 mm or area 916 mm
2 measured by
echocardiography) was used as an indication to perform concomi-
tant pericardial patch augmentation either with ring or suture, and
patients were equally distributed. By 1 year, higher recurrent TR was
present in increasing group order: ring/patch 8%, suture/patch 10%,
isolated ring 14%, and isolated suture 28%. The investigators con-
clude that pericardial patch augmentation technique appears to re-
lieve severe TV tethering; however, this repair technique may be
unsuitable in reoperations and multiple valve surgeries. Careful pa-
tient selection and accurate assessment of preoperative TV tethering
are necessary to prevent repair failure.
TV replacement
& In patients with primary TV disease, TV repair is associated with
better early, mid-term, and event-free survival than TV replacement
(5 years at 90% vs 63%; 10 years at 76% vs 55%; PG0.001) [32].
Moderate to severe RV dysfunction was significantly lower in the TV
repair group (repair, 9%; replacement, 28%). However, in patients
with combined TV and MV disease, Moraca et al. [33￿] found no
difference in survival benefits between TV repair and replacement. In
the propensity-matched study, operative mortality was similar (both
high) for TV repair and replacement (18% vs 13%), and late survival
594 Valvular, Myocardial, Pericardial, and Cardiopulmonary Diseaseswas similar (5 years at 72% vs 79%; 10 years at 66% vs 49%). Other
investigations also demonstrated no difference between procedures,
despite a higher incidence of preoperative TR severity and risk factors
in the TV replacement group [34, 35]. The incidence of redo TV
surgeries was not significantly different between groups [35].
Conclusions
& Reassessment of the current practice guidelines is essential, as we
develop more information on the poor natural history of TR and the
risk factors for late TR with untreated, or inadequately treated, TR
during an earlier surgery. Determining which of the current repair
procedures provide the best long-term outcomes are necessary, in
particular for those patients with severe tethering. Investigations of
adjunctive or other repair techniques are warranted or the use of
chord-sparing TV replacement.
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